{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T03:12:15Z","timestamp":1793416335874,"version":"4.5.0"},"reference-count":138,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ekir.2026.106662","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:26:02Z","timestamp":1781652362000},"page":"106662","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Mineral and Bone Disease in CKD and Kidney Transplantation: Controversies, Gaps, and a Path Forward"],"prefix":"10.1016","volume":"11","author":[{"given":"Mehmet","family":"Kanbay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozgur","family":"Aktas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidar","family":"Copur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilman B.","family":"Drueke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad A.","family":"Massy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2026.106662_bib1","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1186\/s12889-025-21851-z","article-title":"Global, regional, and national burden of chronic kidney disease and its underlying etiologies from 1990 to 2021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"25","author":"Deng","year":"2025","journal-title":"BMC Public Health"},{"key":"10.1016\/j.ekir.2026.106662_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000470909","article-title":"Chronic kidney disease-mineral and bone disorder in Asia","volume":"3","author":"Fukagawa","year":"2017","journal-title":"Kidney Dis (Basel)"},{"key":"10.1016\/j.ekir.2026.106662_bib3","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2026.106662_bib4","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/sj.ki.5001754","article-title":"Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study","volume":"70","author":"Jadoul","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106662_bib5","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.kint.2017.07.021","article-title":"Fractures in patients with CKD-diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation","volume":"92","author":"Pimentel","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106662_bib6","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40620-017-0404-z","article-title":"Osteoporosis, bone mineral density and CKD-MBD: treatment considerations","volume":"30","author":"Bover","year":"2017","journal-title":"J Nephrol"},{"key":"10.1016\/j.ekir.2026.106662_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00198-019-05190-5","article-title":"The association between chronic kidney disease, falls, and fractures: a systematic review and meta-analysis","volume":"31","author":"Goto","year":"2020","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ekir.2026.106662_bib8","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s00198-003-1532-y","article-title":"Long-term fracture risk following renal transplantation: a population-based study","volume":"15","author":"Vautour","year":"2004","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ekir.2026.106662_bib9","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae093","volume":"17","author":"Jorgensen","year":"2024","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2026.106662_bib10","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.kint.2024.11.013","article-title":"Chronic kidney disease-mineral and bone disorder: conclusions from a Kidney Disease: improving Global Outcomes (KDIGO) Controversies Conference","volume":"107","author":"Ketteler","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106662_bib11","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s00223-020-00786-0","article-title":"European Renal osteodystrophy work group aiotCKDMBDwgotERAE. Traditional and non-traditional risk factors for osteoporosis in CKD","volume":"108","author":"Jorgensen","year":"2021","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.ekir.2026.106662_bib12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","article-title":"Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) Guideline Update: what\u2019s changed and why it matters","volume":"92","author":"Ketteler","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106662_bib13","doi-asserted-by":"crossref","first-page":"962","DOI":"10.2215\/CJN.11031017","article-title":"Management of osteoporosis in CKD","volume":"13","author":"Khairallah","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106662_bib14","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1159\/000515542","article-title":"Bone quality in chronic kidney disease patients: current concepts and future directions - Part II","volume":"7","author":"Asadipooya","year":"2021","journal-title":"Kidney Dis (Basel)"},{"key":"10.1016\/j.ekir.2026.106662_bib15","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.kint.2015.12.004","article-title":"Changing bone patterns with progression of chronic kidney disease","volume":"89","author":"Drueke","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106662_bib16","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00223-016-0206-7","article-title":"Novel faces of fibroblast growth factor 23 (FGF23): iron deficiency, inflammation, insulin resistance, left ventricular hypertrophy, proteinuria and acute kidney injury","volume":"100","author":"Kanbay","year":"2017","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.ekir.2026.106662_bib17","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ki.2011.47","article-title":"Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease","volume":"79","author":"Isakova","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106662_bib18","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1053\/j.ackd.2016.03.008","article-title":"CKD-mineral bone disorder in Stage 4 and 5 CKD: what we know today?","volume":"23","author":"Melamed","year":"2016","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.ekir.2026.106662_bib19","article-title":"Immune mechanisms in chronic kidney disease-mineral and bone disorder: current insights and therapeutic implications","volume":"12","author":"Xu","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ekir.2026.106662_bib20","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3390\/toxins16060254","article-title":"Indoxyl sulfate-induced macrophage toxicity and therapeutic strategies in uremic atherosclerosis","volume":"16","author":"Wakamatsu","year":"2024","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.ekir.2026.106662_bib21","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2528956","article-title":"Higher serum uric acid is associated with higher bone mineral density in Chinese men with type 2 diabetes mellitus","volume":"2016","author":"Zhao","year":"2016","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.ekir.2026.106662_bib22","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s40620-019-00615-0","article-title":"The role of uric acid in mineral bone disorders in chronic kidney disease","volume":"32","author":"Afsar","year":"2019","journal-title":"J Nephrol"},{"key":"10.1016\/j.ekir.2026.106662_bib23","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.metabol.2013.09.018","article-title":"Uric acid suppresses 1 alpha hydroxylase in vitro and in vivo","volume":"63","author":"Chen","year":"2014","journal-title":"Metabolism"},{"key":"10.1016\/j.ekir.2026.106662_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2020.592777","article-title":"Association between vitamin D and hyperuricemia among adults in the United States","volume":"7","author":"Zhang","year":"2020","journal-title":"Front Nutr"},{"key":"10.1016\/j.ekir.2026.106662_bib25","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/sj.ki.5002097","article-title":"Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells","volume":"71","author":"Nii-Kono","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106662_bib26","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1093\/ndt\/gfr647","article-title":"Indoxyl sulphate inhibits osteoclast differentiation and function","volume":"27","author":"Mozar","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106662_bib27","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.3390\/ijms21103486","article-title":"Concentration and duration of indoxyl sulfate exposure affects osteoclastogenesis by regulating NFATc1 via aryl hydrocarbon receptor","volume":"21","author":"Liu","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ekir.2026.106662_bib28","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1053\/j.ajkd.2015.08.028","article-title":"Metabolic acidosis of CKD: an update","volume":"67","author":"Kraut","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2026.106662_bib29","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s11255-020-02563-2","article-title":"Complications of metabolic acidosis and alkalinizing therapy in chronic kidney disease patients: a clinician-directed organ-specific primer","volume":"52","author":"Copur","year":"2020","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.ekir.2026.106662_bib30","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1681\/ASN.0000000000000085","article-title":"Comprehensive associations between acidosis and the skeleton in patients with kidney disease","volume":"34","author":"Levy","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106662_bib31","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1159\/000082013","article-title":"Inflammation and vascular calcification","volume":"23","author":"Moe","year":"2005","journal-title":"Blood Purif"},{"key":"10.1016\/j.ekir.2026.106662_bib32","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3390\/biomedicines8120601","article-title":"Expression of circulating microRNAs linked to bone metabolism in chronic kidney disease-mineral and bone disorder","volume":"8","author":"Yavropoulou","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.ekir.2026.106662_bib33","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/ndt\/gfy129","article-title":"Sclerostin in chronic kidney disease-mineral bone disorder think first before you block it","volume":"34","author":"Brandenburg","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106662_bib34","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.kint.2016.12.029","article-title":"The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease","volume":"91","author":"Graciolli","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106662_bib35","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2215\/CJN.07670712","article-title":"The relation between renal function and serum sclerostin in adult patients with CKD","volume":"8","author":"Pelletier","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106662_bib36","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1093\/ndt\/gft234","article-title":"Disturbances of Wnt\/beta-catenin pathway and energy metabolism in early CKD: effect of phosphate binders","volume":"28","author":"de Oliveira","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106662_bib37","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1093\/ckj\/sfab081","article-title":"Sclerostin and DKK1 circulating levels associate with low bone turnover in patients with chronic kidney disease Stages 3 and 4","volume":"14","author":"Neto","year":"2021","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2026.106662_bib38","doi-asserted-by":"crossref","first-page":"E1854","DOI":"10.1210\/jc.2014-2042","article-title":"Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients","volume":"99","author":"Kanbay","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ekir.2026.106662_bib39","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1007\/s11255-016-1387-8","article-title":"Sclerostin, cardiovascular disease and mortality: a systematic review and meta-analysis","volume":"48","author":"Kanbay","year":"2016","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.ekir.2026.106662_bib40","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1172\/JCI133473","article-title":"Parathyroid hormone-dependent bone formation requires butyrate production by intestinal microbiota","volume":"130","author":"Li","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ekir.2026.106662_bib41","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.kint.2020.03.004","article-title":"Gut microbiota orchestrates PTH action in bone: role of butyrate and T cells","volume":"98","author":"Massy","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106662_bib42","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-02865-0","article-title":"Butyrate producing microbiota are reduced in chronic kidney diseases","volume":"11","author":"Gao","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ekir.2026.106662_bib43","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s00198-012-2112-9","article-title":"The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study","volume":"24","author":"Fraser","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ekir.2026.106662_bib44","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/archinte.168.7.735","article-title":"Loop diuretic use and increased rates of hip bone loss in older men: the Osteoporotic Fractures in Men Study","volume":"168","author":"Lim","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ekir.2026.106662_bib45","doi-asserted-by":"crossref","first-page":"590","DOI":"10.2215\/CJN.06420909","article-title":"Vitamins K and D status in stages 3\u20135 chronic kidney disease","volume":"5","author":"Holden","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106662_bib46","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s11255-012-0367-x","article-title":"Vitamin K status in chronic kidney disease: a report of a study and a mini-review","volume":"45","author":"Voong","year":"2013","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.ekir.2026.106662_bib47","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3945\/an.111.001644","article-title":"Vitamin K status and vascular calcification: evidence from observational and clinical studies","volume":"3","author":"Shea","year":"2012","journal-title":"Adv Nutr"},{"key":"10.1016\/j.ekir.2026.106662_bib48","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.3390\/nu12061609","article-title":"Current therapy in CKD patients can affect vitamin K status","volume":"12","author":"Cozzolino","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.ekir.2026.106662_bib49","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00198-007-0394-0","article-title":"Glucocorticoid-induced osteoporosis: pathophysiology and therapy","volume":"18","author":"Canalis","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ekir.2026.106662_bib50","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00223-020-00779-z","article-title":"Bone fragility fractures in CKD patients","volume":"108","author":"Pimentel","year":"2021","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.ekir.2026.106662_bib51","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/ckj\/sfac230","article-title":"Management of fracture risk in CKD-traditional and novel approaches","volume":"16","author":"Haarhaus","year":"2023","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2026.106662_bib52","doi-asserted-by":"crossref","DOI":"10.1177\/20543581211041184","article-title":"T scores, FRAX, Frailty phenotype, falls, and its relationship to fractures in patients on maintenance hemodialysis","volume":"8","author":"Jafari","year":"2021","journal-title":"Can J Kidney Health Dis"},{"key":"10.1016\/j.ekir.2026.106662_bib53","doi-asserted-by":"crossref","DOI":"10.1002\/jcsm.13787","article-title":"Osteosarcopenia in chronic kidney disease: an overlooked syndrome?","volume":"16","author":"Caldiroli","year":"2025","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ekir.2026.106662_bib54","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ki.2013.279","article-title":"High rates of death and hospitalization follow bone fracture among hemodialysis patients","volume":"85","author":"Tentori","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106662_bib55","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.2215\/CJN.02150218","article-title":"Protein energy wasting in hemodialysis patients","volume":"13","author":"Sarav","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106662_bib56","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1017\/S0007114519000400","article-title":"Criteria for classification of protein-energy wasting in dialysis patients: impact on prevalence","volume":"121","author":"Gracia-Iguacel","year":"2019","journal-title":"Br J Nutr"},{"key":"10.1016\/j.ekir.2026.106662_bib57","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1053\/j.jrn.2013.01.001","article-title":"Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM)","volume":"23","author":"Carrero","year":"2013","journal-title":"J Ren Nutr"},{"key":"10.1016\/j.ekir.2026.106662_bib58","first-page":"763","article-title":"The malnutrition inflammation complex syndrome-the micsing factor in the perio-chronic kidney disease interlink","volume":"7","author":"Anand","year":"2013","journal-title":"J Clin Diagn Res"},{"key":"10.1016\/j.ekir.2026.106662_bib59","article-title":"Bone and mineral disorder in renal transplant patients: overview of pathology, clinical, and therapeutic aspects","volume":"9","author":"Molinari","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ekir.2026.106662_bib60","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1097\/01.ASN.0000129337.50739.48","article-title":"Arterial calcifications and bone histomorphometry in end-stage renal disease","volume":"15","author":"London","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106662_bib61","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3390\/ijms17040613","article-title":"Unfractionated heparin promotes osteoclast formation in vitro by inhibiting osteoprotegerin activity","volume":"17","author":"Li","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ekir.2026.106662_bib62","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.3390\/ijms20215275","article-title":"Anticoagulants and osteoporosis","volume":"20","author":"Signorelli","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ekir.2026.106662_bib63","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfaf228","article-title":"Management of osteoporosis in chronic kidney disease","volume":"18","author":"Henry","year":"2025","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2026.106662_bib64","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00198-025-07422-3","volume":"36","author":"Bhattoa","year":"2025","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ekir.2026.106662_bib65","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1053\/j.ajkd.2015.06.023","article-title":"Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis","volume":"67","author":"Sprague","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2026.106662_bib66","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1053\/j.ajkd.2021.06.031","article-title":"Diagnosis and management of osteoporosis in advanced kidney disease: a review","volume":"79","author":"Ginsberg","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2026.106662_bib67","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/JIM.0000000000000153","article-title":"Associations of fibroblast growth factor 23 and fetuin-A with coronary plaque burden and plaque composition in young adults","volume":"63","author":"Akin","year":"2015","journal-title":"J Investig Med"},{"key":"10.1016\/j.ekir.2026.106662_bib68","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jdiacomp.2015.02.013","article-title":"Relationship of fibroblast growth factor 23 and fetuin--A to coronary atherosclerosis","volume":"29","author":"Akin","year":"2015","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.ekir.2026.106662_bib69","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.2215\/CJN.02560310","article-title":"Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease","volume":"5","author":"Kanbay","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106662_bib70","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s11255-011-0076-x","article-title":"Association of serum calcitonin with coronary artery disease in individuals with and without chronic kidney disease","volume":"44","author":"Kanbay","year":"2012","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.ekir.2026.106662_bib71","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.2215\/CJN.12871211","article-title":"Bone mineral density and fracture risk in older individuals with CKD","volume":"7","author":"Yenchek","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106662_bib72","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfr317","article-title":"Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients--a single-center cohort study","volume":"27","author":"Iimori","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106662_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2022.116482","article-title":"Vascular calcification of the abdominal aorta has minimal impact on lumbar spine bone density in patients with chronic kidney disease","volume":"162","author":"Jorgensen","year":"2022","journal-title":"Bone"},{"key":"10.1016\/j.ekir.2026.106662_bib74","doi-asserted-by":"crossref","first-page":"646","DOI":"10.2215\/CJN.06040614","article-title":"Comparison of fracture risk prediction among individuals with reduced and normal kidney function","volume":"10","author":"Naylor","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106662_bib75","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.kint.2018.09.022","article-title":"The Fracture Risk Assessment Tool (FRAX(R)) predicts fracture risk in patients with chronic kidney disease","volume":"95","author":"Whitlock","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106662_bib76","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00198-013-2524-1","article-title":"The clinical utility of FRAX to discriminate fracture status in men and women with chronic kidney disease","volume":"25","author":"Jamal","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ekir.2026.106662_bib77","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.2215\/CJN.09711010","article-title":"Bone microarchitecture in hemodialysis patients assessed by HR-pQCT","volume":"6","author":"Cejka","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106662_bib78","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/jbmr.1916","article-title":"Rapid cortical bone loss in patients with chronic kidney disease","volume":"28","author":"Nickolas","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ekir.2026.106662_bib79","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/jbmr.2176","article-title":"Trabecular bone score: a noninvasive analytical method based upon the DXA image","volume":"29","author":"Silva","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ekir.2026.106662_bib80","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s12020-014-0280-4","article-title":"Utility of the trabecular bone score (TBS) in secondary osteoporosis","volume":"47","author":"Ulivieri","year":"2014","journal-title":"Endocrine"},{"key":"10.1016\/j.ekir.2026.106662_bib81","doi-asserted-by":"crossref","first-page":"e1534","DOI":"10.1210\/clinem\/dgad724","article-title":"Trabecular bone score as a marker of skeletal fragility across the spectrum of chronic kidney disease: a systematic review and meta-analysis","volume":"109","author":"Bioletto","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ekir.2026.106662_bib82","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2265.2011.04265.x","article-title":"Bone turnover markers predict changes in bone mineral density after parathyroidectomy in patients with renal hyperparathyroidism","volume":"76","author":"Lu","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ekir.2026.106662_bib83","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1007\/s00268-019-05020-z","article-title":"Cardiovascular and cerebrovascular events after parathyroidectomy in patients on renal replacement therapy","volume":"43","author":"Ivarsson","year":"2019","journal-title":"World J Surg"},{"key":"10.1016\/j.ekir.2026.106662_bib84","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1080\/0886022X.2016.1184924","article-title":"Long-term mortality after parathyroidectomy among chronic kidney disease patients with secondary hyperparathyroidism: a systematic review and meta-analysis","volume":"38","author":"Chen","year":"2016","journal-title":"Ren Fail"},{"key":"10.1016\/j.ekir.2026.106662_bib85","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/sdi.12772","article-title":"Parathyroidectomy in dialysis patients: indications, methods, and consequences","volume":"32","author":"Rodr\u00edguez-Ortiz","year":"2019","journal-title":"Semin Dial"},{"key":"10.1016\/j.ekir.2026.106662_bib86","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/ndt\/gfaa192","article-title":"European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4-G5D","volume":"36","author":"Evenepoel","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106662_bib87","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/jbmr.4235","article-title":"Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease: a binational cohort analysis","volume":"36","author":"Robinson","year":"2021","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ekir.2026.106662_bib88","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/jama.2023.28239","article-title":"Severe hypocalcemia with denosumab among older female dialysis-dependent patients","volume":"331","author":"Bird","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2026.106662_bib89","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00198-006-0189-8","article-title":"Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment","volume":"18","author":"Miller","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ekir.2026.106662_bib90","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.2147\/CIA.S120175","article-title":"Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: post hoc analysis of a postmarketing observational study","volume":"11","author":"Nishikawa","year":"2016","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.ekir.2026.106662_bib91","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/ckj\/sfx125","article-title":"Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes","volume":"11","author":"Pereira","year":"2018","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2026.106662_bib92","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s40265-016-0671-3","article-title":"Etelcalcetide: first global approval","volume":"76","author":"Etelcalcetide","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.ekir.2026.106662_bib93","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jama.2016.19468","article-title":"Effect of etelcalcetide vs Cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2026.106662_bib94","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1053\/j.ajkd.2020.02.439","article-title":"Comparative effectiveness of calcimimetic agents for secondary hyperparathyroidism in adults: a systematic review and network meta-analysis","volume":"76","author":"Palmer","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2026.106662_bib95","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/j.1523-1755.2005.00596.x","article-title":"Effects of the calcimimetic Cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism","volume":"68","author":"Cunningham","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106662_bib96","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/ki.2014.349","article-title":"Bone histomorphometry before and after long-term treatment with Cinacalcet in dialysis patients with secondary hyperparathyroidism","volume":"87","author":"Behets","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106662_bib97","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.kint.2018.05.013","article-title":"Head-to-head comparison of the new calcimimetic agent evocalcet with Cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism","volume":"94","author":"Fukagawa","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106662_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175936","article-title":"Pharmacological profile of upacicalcet, a novel positive allosteric modulator of calcium-sensing receptor, in vitro and in vivo","volume":"956","author":"Goto","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.ekir.2026.106662_bib99","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106662_bib100","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1210\/jc.2017-02163","article-title":"A Phase III randomized placebo-controlled trial to evaluate efficacy and safety of Romosozumab in men with osteoporosis","volume":"103","author":"Lewiecki","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ekir.2026.106662_bib101","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s00223-022-01031-6","article-title":"One-year Romosozumab treatment followed by one-year denosumab treatment for osteoporosis in patients on hemodialysis: an observational study","volume":"112","author":"Saito","year":"2023","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.ekir.2026.106662_bib102","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1007\/s00774-021-01253-y","article-title":"Efficacy of Romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study","volume":"39","author":"Sato","year":"2021","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.ekir.2026.106662_bib103","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/TP.0000000000003137","article-title":"Summary of the kidney disease: improving global outcomes (KDIGO) clinical practice guideline on the evaluation and management of candidates for kidney transplantation","volume":"104","author":"Chadban","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2026.106662_bib104","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.2215\/CJN.02460310","article-title":"Measuring total blood calcium displays a low sensitivity for the diagnosis of hypercalcemia in incident renal transplant recipients","volume":"5","author":"Evenepoel","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106662_bib105","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/TP.0000000000000823","article-title":"A prospective cohort study of mineral metabolism after kidney transplantation","volume":"100","author":"Wolf","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2026.106662_bib106","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nrneph.2015.153","article-title":"Phosphate and FGF-23 homeostasis after kidney transplantation","volume":"11","author":"Baia","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2026.106662_bib107","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/j.1600-6143.2007.01753.x","article-title":"Tertiary \u2018hyperphosphatoninism\u2019 accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients","volume":"7","author":"Evenepoel","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2026.106662_bib108","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2215\/CJN.03410321","article-title":"Bone and mineral disease in kidney transplant recipients","volume":"17","author":"Khairallah","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106662_bib109","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1093\/ndt\/10.11.2096","article-title":"Bone loss after kidney transplantation: a longitudinal study in 115 graft recipients","volume":"10","author":"Grotz","year":"1995","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106662_bib110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.5650090102","article-title":"Changes in bone mass early after kidney transplantation","volume":"9","author":"Horber","year":"1994","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ekir.2026.106662_bib111","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1001\/jama.288.23.3014","article-title":"Risk of hip fracture among dialysis and renal transplant recipients","volume":"288","author":"Ball","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2026.106662_bib112","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/TP.0000000000000808","article-title":"Fracture incidence in adult kidney transplant recipients","volume":"100","author":"Naylor","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2026.106662_bib113","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1689233","article-title":"Comparative efficacy and safety of anti-osteoporotic therapies for kidney transplant recipients: a systematic review and network meta-analysis","volume":"16","author":"Liu","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ekir.2026.106662_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2022.100474","article-title":"Kidney transplantation, immunosuppression and the risk of fracture: clinical and economic implications","volume":"4","author":"Kuppachi","year":"2022","journal-title":"Kidney Med"},{"key":"10.1016\/j.ekir.2026.106662_bib115","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1111\/j.1600-6143.2008.02327.x","article-title":"Effect of teriparatide on early bone loss after kidney transplantation","volume":"8","author":"Cejka","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2026.106662_bib116","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s11255-025-04383-8","article-title":"Efficacy and safety of teriparatide in kidney transplant recipients with osteoporosis and low bone turnover: a real-world experience","volume":"57","author":"Vetrano","year":"2025","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.ekir.2026.106662_bib117","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.kint.2025.11.019","article-title":"Parathyroid hormone suppression profiles following oral calcium challenge in kidney transplant recipients","volume":"109","author":"Desenclos","year":"2026","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106662_bib118","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106662_bib119","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfad290","article-title":"Real-world usage of chronic kidney disease\u2013mineral bone disorder (CKD-MBD) biomarkers in nephrology practices","volume":"17","author":"Fusaro","year":"2024","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2026.106662_bib120","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/ndt\/gfq602","article-title":"Improving CKD-MBD management in haemodialysis patients: barrier analysis for implementing better practice","volume":"26","author":"Toussaint","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106662_bib121","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/hdi.12315","article-title":"Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers: findings from the DOPPS","volume":"20","author":"Fissell","year":"2016","journal-title":"Hemodial Int"},{"key":"10.1016\/j.ekir.2026.106662_bib122","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s12020-021-02735-9","article-title":"A review and perspective on the assessment, management and prevention of fragility fractures in patients with osteoporosis and chronic kidney disease","volume":"73","author":"Hampson","year":"2021","journal-title":"Endocrine"},{"key":"10.1016\/j.ekir.2026.106662_bib123","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1007\/s00198-021-05975-7","article-title":"Diagnosis and management of osteoporosis in chronic kidney disease stages 4 to 5D: a call for a shift from nihilism to pragmatism","volume":"32","author":"Evenepoel","year":"2021","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ekir.2026.106662_bib124","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1053\/j.ajkd.2023.05.016","article-title":"Comparative effectiveness of alternative treatment approaches to secondary hyperparathyroidism in patients receiving maintenance hemodialysis: an observational trial emulation","volume":"83","author":"Platt","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2026.106662_bib125","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.34067\/KID.0000000000000262","article-title":"Managing phosphate burden in patients receiving dialysis: beyond phosphate binders and diet","volume":"4","author":"Kalantar-Zadeh","year":"2023","journal-title":"Kidney360"},{"key":"10.1016\/j.ekir.2026.106662_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2025.117653","article-title":"Dysregulation of bone and myocardial inorganic phosphate transporters and downstream cell signals in early-stage mild chronic kidney disease-mineral and bone disorder: an experimental study","volume":"201","author":"Bogdanova","year":"2025","journal-title":"Bone"},{"key":"10.1016\/j.ekir.2026.106662_bib128","doi-asserted-by":"crossref","first-page":"7270","DOI":"10.3390\/ijms24087270","article-title":"Mild chronic kidney disease associated with low bone formation and decrease in phosphate transporters and signaling pathways gene expression","volume":"24","author":"Bogdanova","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ekir.2026.106662_bib129","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/bcp.13863","article-title":"A phase 1b randomized, placebo-controlled clinical trial with SNF472 in haemodialysis patients","volume":"85","author":"Salcedo","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ekir.2026.106662_bib130","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1161\/CIRCULATIONAHA.119.044195","article-title":"Slowing progression of cardiovascular calcification with SNF472 in patients on hemodialysis: results of a randomized Phase 2b study","volume":"141","author":"Raggi","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2026.106662_bib131","doi-asserted-by":"crossref","first-page":"736","DOI":"10.2215\/CJN.16931020","article-title":"Effects of myo-inositol hexaphosphate (SNF472) on bone mineral density in patients receiving hemodialysis: an analysis of the randomized, placebo-controlled CaLIPSO study","volume":"16","author":"Bushinsky","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106662_bib132","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.10068","article-title":"Intravenous sodium thiosulphate for calciphylaxis of chronic kidney disease: a systematic review and meta-analysis","volume":"6","author":"Wen","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ekir.2026.106662_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102784","article-title":"Hexasodium fytate for the treatment of calciphylaxis: a randomised, double-blind, phase 3, placebo-controlled trial with an open-label extension","volume":"75","author":"Sinha","year":"2024","journal-title":"EClinicalmedicine"},{"key":"10.1016\/j.ekir.2026.106662_bib134","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.kint.2017.04.011","article-title":"Dietary magnesium supplementation prevents and reverses vascular and soft tissue calcifications in uremic rats","volume":"92","author":"Diaz-Tocados","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106662_bib135","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1681\/ASN.0000000000000092","article-title":"The effect of magnesium supplementation on vascular calcification in CKD: a randomized clinical trial (MAGiCAL-CKD)","volume":"34","author":"Bressendorff","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106662_bib136","doi-asserted-by":"crossref","DOI":"10.1080\/0886022X.2023.2182603","article-title":"Effect of magnesium on vascular calcification in chronic kidney disease patients: a systematic review and meta-analysis","volume":"45","author":"Zhan","year":"2023","journal-title":"Ren Fail"},{"key":"10.1016\/j.ekir.2026.106662_bib137","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.kint.2016.02.002","article-title":"Ligand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease","volume":"89","author":"Agapova","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106662_bib138","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.3390\/ijms19092490","article-title":"Systemic activation of activin A signaling causes chronic kidney disease-mineral bone disorder","volume":"19","author":"Sugatani","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ekir.2026.106662_bib139","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.ekir.2019.08.001","article-title":"Sotatercept safety and effects on hemoglobin, bone, and vascular calcification","volume":"4","author":"Coyne","year":"2019","journal-title":"Kidney Int Rep"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926028949?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926028949?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T09:21:05Z","timestamp":1788427265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024926028949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":138,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2468024926028949"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2026.106662","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mineral and Bone Disease in CKD and Kidney Transplantation: Controversies, Gaps, and a Path Forward","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2026.106662","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}],"article-number":"106662"}}